LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.07 USD | -2.46% |
|
+2.76% | -30.08% |
| 11-13 | Genscript Bio Associate Legend Biotech's Loss Doubles in Q3 | MT |
| 11-12 | Legend Biotech Q3 Loss Widens, Revenue Rises | MT |
Summary: Legend Biotech Corporation
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Highlights: Legend Biotech Corporation
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: Legend Biotech Corporation
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings Chart: Legend Biotech Corporation
Source: Surperformance
ESG chart: Legend Biotech Corporation
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| - | 7.72B | ||||
| 121B | |||||
| 80.72B | |||||
| 37.35B | |||||
| 28.38B | |||||
| - | 22.84B | ||||
| 19.65B | |||||
| 13.72B | |||||
| - | 13.45B | ||||
| Average | 38.26B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
D
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LEGN Stock
- Ratings Legend Biotech Corporation
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition